Home' Australian Pharmacist : Australian Pharmacist January 2013 Contents Australian Pharmacist January 2013 I ©Pharmaceutical Society of Australia Ltd. 39
the possibility of giant cell arteritis as a
cause of the patient's symptoms. Mrs AC
was subsequently subjected to temporal
artery biopsy which confirmed giant
cell arteritis and she was placed on high
dose prednisolone. The steroid dose was
gradually tapered and Mrs AC is currently
on prednisolone 5 mg daily with no
complete recovery as yet (after 20 months).
There was no improvement of her
hearing loss. She still has mild headache
occasionally. Mrs AC had transient vision
loss and her vision was saved due to
prompt treatment with corticosteroids.
She is seen by her eye specialist every six
months in relation to giant cell arteritis.
1. Afshari NA, Afshari MA, Lessell S. Temporal arteritis. Int
Ophthalmol Clin 2001;41(1):151--8.
2. Roome P, Hazleman B, Eve R. A suspected case of temporal
arteritis. Practitioner 2001;245(1624)577:81, 84--6.
3. Villa-Forte A. Giant cell arteritis: suspect it, treat it promptly. Cleve
Clin J Med 2011;78(4):265--70.
4. Schmidt J, Warrington KJ. Polymyalgia rheumatica and giant
cell arteritis in older patients: diagnosis and pharmacological
management. Drugs Aging 2011;28(8):651--66.
5. Paraskevas KI, Boumpas DT, Vrentzos GE, Mikhailidis DP. Oral and
ocular/orbital manifestations of temporal arteritis: a disease with
deceptive clinical symptoms and devastating consequences. Clin
6. Harder N. Temporal arteritis: an approach to suspected
vasculitides. Prim Care 2010;37(4):757--66.
7. Hazel E, Starr M. Giant cell arteritis: an update on diagnosis and
management. Geriatr Aging 2007;10(6):389--392.
8. Frearson R, Cassidy T, Newton J. Polymyalgia rheumatica and
temporal arteritis: evidence and guidelines for diagnosis and
management in older people. Age Ageing 2003;32(4):370--4.
9. Michail M. Fifty is definitely not the new forty. Aust Pharmacist
10. Mohan SV, Liao YJ, Kim JW, et al. Giant cell arteritis: immune
and vascular aging as disease risk factors. Arthritis Res Ther
11. Weyand CM, Goronzy JJ. Pathogenic mechanisms in giant cell
arteritis. Cleve Clin J Med 2002;69 Suppl 2:SII28-32.
12. Hayreh SS, Podhajsky PA, Raman R, et al. Giant cell arteritis: validity
and reliability of various diagnostic criteria. Am J Ophthalmol
13. Pfadenhauer K, Roesler A, Golling A. The involvement of the
peripheral nervous system in biopsy proven active giant cell
arteritis. J Neurol 2007;254(6):751--5.
14. Smeeth L, Cook C, Hall AJ. Incidence of diagnosed polymyalgia
rheumatica and temporal arteritis in the United Kingdom, 1990-
2001. Ann Rheum Dis 2006;65(8):1093--8.
15. Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and
giant-cell arteritis. N Engl J Med 2002;347(4):261--71.
16. Dasgupta B, Matteson EL, Maradit-Kremers H. Management
guidelines and outcome measures in polymyalgia rheumatica
(PMR). Clin Exp Rheumatol 2007;25(6 Suppl 47):130--6.
17. Polymyalgia rheumatica and giant cell arteritis [revised 2010 Oct].
In: eTG complete [CD-ROM]. Melbourne: Therapeutic Guidelines;
2012 Jul, etg37.
18. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and
giant-cell arteritis. Lancet 2008;372(9634):234--45.
19. Hayreh SS, Zimmerman B. Management of giant cell arteritis.
Our 27-year clinical study: new light on old controversies. Int J
20. Arnold AC. Ischemic optic neuropathy. In: Miller NR, Newman NJ,
Biousse V et al, eds. Clinical neuro-ophthalmology, vol. 1. 6th edn.
Philadelphia: Williams & Wilkins; 2005. p. 349--84.
21. Kawasaki A, Purvin V. Giant cell arteritis: an updated review. Acta
22. Ness T, Auw-Hadrich C, Schmidt D. Temporal arteritis (giant
cell arteritis). Clinical picture, histology, and treatment.
23. Schmidt WA. Current diagnosis and treatment of temporal
arteritis. Curr Treat Options Cardiovasc Med 2006;8(2):145--51.
24. Zhou L, Luneau K, Weyand CM, et al. Clinicopathologic
correlations in giant cell arteritis: a retrospective study of 107
cases. Ophthalmol 2009;116(8):1574--80.
25. Borchers AT, Gershwin ME. Giant cell arteritis: a review of
classification, pathophysiology, geoepidemiology and treatment.
Autoimmun Rev 2012;11(6-7):A544--54.
26. Prevention of osteoporosis [revised Jun 2009]. In: eTG complete
[CD-ROM]. Melbourne: Therapeutic Guidelines; 2012 Jul, etg37.
Transition care helps
Almost half of all older people who left
hospital and received assistance through
the Transition Care Program (TCP) returned
to the community in 2010--11, according
to a report released by the Australian
Institute of Health and Welfare (AIHW).
The report, Older people leaving hospital:
a statistical overview of the Transition Care
Program 2009-10 and 2010-11, presents
recent statistics and examines some
TCP has been operating since 2005--06,
and provides short-term care to older
people who would be assessed as
otherwise eligible for at least low-level
residential care as they leave hospital.
It aims to improve clients' independence
and functioning and delay entry into
residential aged care.
The report shows that of the people who
received any care under the program in
2010--11, 56% had improved functioning
during their care and more than 8,400
(49%) returned to the community.
A further 19% of recipients entered
residential care, 23% returned to hospital
and 2% died.
AIHW spokesperson Brent Diverty said:
'The number of people receiving care as
part of the program increased from about
15,000 in 2009--10 to about 18,000 in
'Overall, looking at those who completed
their planned care, about 75% had
improved functional capacity afterwards.
A further 17% maintained their existing
level of function, while functional
capacity deteriorated for 8% of recipients.
'Over the six years since its introduction,
more than 60% of recipients left the
program with an improved level of
functioning. And since 2005--06, the
proportion of care recipients who
returned to the community has been
about 54% overall.'
Study uncovers mothers/child
Over the past 30 years researchers at
The University of Queensland (UQ) have
been documenting the lives of mothers
and their children to uncover what role
genetic and environmental factors have
on mental illness, substance abuse and
The researchers, including researchers
from the School of Pharmacy, led by UQ's
School of Population Health and School
of Social Science Professor Jake Najman
say their latest study was investigating the
causes of common mental disorders such
as anxiety, depression and substance use.
The study followed a sample of 4,000
mothers and 4,000 children, from birth
to 30 years of age. One of the aims was to
see the extent to which the mental health
of the mother can predict the mental
health of the child, when that child is the
Professor Najman said that the findings
showed over half of the 4,000 Australian
young adults involved in the study had
ever had a diagnosable mental illness.
'The research will provide important
information to influence the treatment and
prevention of these disorders,' he said.
The common mental disorders
cumulatively make the largest contribution
to morbidity in developed countries and
despite this, relatively little is known about
the factors that lead to the onset and
recurrence of these disorders over the
early life span. The research was conducted
as part of the Mater-University Study of
Pregnancy (MUSP), a longitudinal study of
over 8,000 mothers and their children born
at Brisbane's Mater Hospital in Australia
The research team already has detailed
data on this sample of young adults from
pregnancy, six months after the birth,
five years, 14 years and 21 year follow-up
data. Participants have been asked to
share information about their family life,
substance abuse and any health issues
they have had.
The research team is currently looking
for another 4,000 participants who were
involved in the study and have been lost
over the duration of the study.
All papers that have been published
on the Mater-University of Queensland
Study of Pregnancy including 12
papers published in 2012 are availalbe
Links Archive Australian Pharmacist December 2012 February 2013 Navigation Previous Page Next Page